A 31-year-old female with lymphoblastic lymphoma developed myasthenia gravis (MG) 26 months after receiving an allogeneic bone marrow transplant (BMT) from an HLA-identical sister. She presented with classic symptoms and electromyographic evidence of the disorder approximately 2 weeks after electing to abruptly discontinue her immunosuppressive medications. She initially responded to steroids and acetylcholinesterase inhibitors. Her subsequent course has been characterized by episodes of moderately severe weakness that respond to intravenous immunoglobulin and prednisone. This case of post-transplant MG is only the second reported to have occurred in association with BMT for lymphoblastic lymphoma. Potential risk factors for the development of post-transplant MG are discussed including underlying hematological disorder, HLA phenotype, family history of MG, the presence of chronic GVHD, and recent cessation of immune suppression. Keywords: myasthenia gravis; allogeneic bone marrow transplant; lymphoblastic lymphoma; graft-versus-host disease
thenia gravis following the abrupt cessation of immunosuppressive therapy for chronic GVHD.
A 31-year-old female was diagnosed with lymphoblastic lymphoma in July 1994. She had a good response to initial treatment but subsequently relapsed while on maintenance therapy. In April 1996, she underwent an allogeneic BMT from her HLA-identical sister (A2, A26, B38, B18, Bw4, Bw6, Cw7, DR1, DR15, DQ5,6, DR51). She developed acute GVHD with skin and gastrointestinal tract involvement and was treated with cyclosporine and methylprednisolone which were gradually tapered off by 11 months post transplant. Two months later she began to develop skin thickening and ulceration consistent with chronic GVHD. Cyclosporine and methylprednisolone were restarted and over the ensuing months she also received etretinate and mycophenolate with modest improvement. In June 1998, she discontinued her immunosuppressive medications without consulting with her physicians. At that time, she was taking prednisone 5 mg every other day, cyclosporine 125 mg every other day, and mycophenolate 1000 mg twice daily. Two weeks later she presented with bilateral ptosis and diplopia. Over the 2 days prior to presentation, she also noted jaw fatigue with mastication, intermittent leg weakness, and dyspnea. Examination revealed bilateral ptosis, slight masseter weakness, hoarseness, and mild proximal muscle weakness. Edrophonium (10 mg administered by slow intravenous push) produced a marked transient improvement in her ptosis and masseter weakness. EMG revealed the typical decrementing response to repetitive stimulation consistent with myasthenia gravis. Antibodies to the acetylcholine receptor were elevated at 4.8 nmol/l. She was started on pyridostigmine (60 mg by mouth every 4 h), prednisone (1 mg/kg per day in divided doses), and cyclosporine (100 mg by mouth twice daily). Because of persistent dyspnea, the pyridostigmine was increased to 90 mg every 4 h. On this regimen her strength improved and the dyspnea resolved. On the seventh hospital day, she was discharged home. Three days later she presented to the emergency room with profound dyspnea and impending respiratory failure. She was intubated and admitted to the intensive care unit where she received intravenous steroids and pyridostigmine at a dose of 120 mg every 4 h. On this regimen her strength improved, and she was successfully extubated on hospital day 4. She was discharged home taking prednisone 40 mg twice daily and pyridostigmine 120 mg every 4 h. Her subsequent course has been characterized by moderately severe fluctuating weakness that has required monthly intravenous immunoglobulin and prednisone 80 mg every other day.
Discussion
Myasthenia gravis has been reported in several patients following allogeneic BMT. All of the patients reported in the literature except one have had active chronic GVHD, and many had recently decreased or discontinued their immunosuppression. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] It has therefore been postulated that the development of myasthenia gravis following allogeneic BMT may be an unusual manifestation of chronic GVHD. Studies have shown that over 20% of patients who undergo allogeneic BMT develop autoantibodies to the acetylcholine receptor, but only a distinct minority of these patients go on to develop clinical evidence of myasthenia gravis. 13, 14 The factors that predispose to the development of myasthenia gravis following allogeneic BMT remain obscure. A recent review of the reported cases attempted to identify whether specific HLA antigens are present at increased frequencies in these patients. HLA Cw1, Cw7 and DR2 were identified at frequencies significantly above the expected based on HLA prevalence studies. 11 Of note, the patient in the present discussion did express the HLA antigen Cw7. Although certain HLA antigens may represent markers for increased risk of the development of myasthenia gravis after allogeneic BMT, the low incidence of this disorder will make it difficult to establish this definitively.
It is well established that family members of patients with myasthenia gravis are at increased risk of developing this condition. Our patient noted that she had a paternal grandmother with myasthenia. One additional patient with post-transplant myasthenia gravis has been reported who had a paternal grandfather who suffered from the disorder. 11 Acetylcholine receptor antibody studies were obtained on the donors in six of the previously reported cases of post-transplant myasthenia gravis, and in all cases they were within the normal range. [1] [2] [3] 5, 8, 11 In one instance, electromyographic studies were also obtained from the donor. 1 They revealed subtle abnormalities occasionally seen in asymptomatic relatives of patients with myasthenia gravis that the authors felt might suggest a predisposition to the disorder. In the present case, acetylcholine antibody studies were not obtained from the donor, but she had no clinical signs of myasthenia gravis. The present evidence suggests that allogeneic BMT patients with a family history of myasthenia gravis may be at increased risk of developing this disorder post BMT. However, definitive proof of a donor origin for this complication is lacking.
Seven of the 15 patients reported in the literature with post-transplant myasthenia gravis were transplanted for aplastic anemia. This represents an extreme disproportion given that aplastic anemia accounts for only approximately 7% of allogeneic transplants. 15 However, the relationship between the underlying disease state and the development of myasthenia gravis after transplantation remains to be established. Lymphoblastic lymphoma has not been previously associated with myasthenia gravis after transplantation, although one patient with T cell ALL has been reported in association with this phenomenon. 5 One group has reported the presence of autoantibodies directed against the acetylcholine receptor in certain hematological disorders, notably aplastic anemia and acute non-lymphocytic leukemia. 16 The presence of these antibodies prior to transplantation has been evaluated in only four of the reported cases of post-transplant myasthenia. One patient with aplastic anemia had an elevated acetylcholine receptor antibody level prior to allogeneic BMT. 2 Three additional patients with aplastic anemia had antibody levels no different than controls. 1, 3 It remains to be established whether the underlying hematological disorder predisposes certain patients to the development of myasthenia gravis after allogeneic BMT.
Myasthenia gravis is a well-described neuromuscular complication of allogeneic BMT. The patients who are at increased risk for the development of this complication remain poorly defined. The disorder is generally treatable with acetylcholinesterase inhibitors and immunosuppressive therapy, and early institution of treatment can prevent serious complications such as respiratory compromise and the need for mechanical ventilation. Since failure to detect this disorder may have fatal consequences, physicians should consider the diagnosis in all of their transplant patients who present with unexplained muscle weakness, especially those with chronic GVHD in whom immunosuppressive therapy has recently been tapered or discontinued.
